The advanced, metastatic differentiated thyroid cancers (DTCs) have a poor prognosis
mainly owing to radioactive iodine (RAI) refractoriness caused by decreased expression of …

Most malignant thyroid tumours are initially treated with surgery or a combination of surgery
and radioactive iodine (RAI) therapy. However, in patients with metastatic disease, many …

PURPOSE Anaplastic thyroid cancer (ATC), an aggressive malignancy, is associated with a
poor prognosis and an unmet need for effective treatment, especially for patients without …

Iodine-resistant cancers account for the vast majority of thyroid related mortality and, until
recently, there were limited therapeutic options. However, over the last decade our …

Targeted therapies have reshaped the landscape of the development of cancer
therapeutics. Recent biomarker‐driven, tissue‐agnostic clinical trials represent a significant …

Anaplastic thyroid cancer is an extremely lethal malignancy without reliable treatment.
BRAFV600E point mutation is common in ATCs, which leads to MAPK signaling activation …

For differentiated thyroid cancer (DTC), systemic therapy with radioactive iodine (RAI) is
utilized for radiosensitive disease, while for radioiodine refractory (RAIR) disease, current …

Gain-of-function of V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF) is one of the
most frequent oncogenic mutations in numerous cancers, including thyroid papillary …

Some new Bis-pyrazoline hybrids 8–17 with dual EGFR and BRAFV600E inhibitors have
been developed. The target compounds were synthesized and tested in vitro against four …

Among follicular-derived thyroid cancers (TC), those with aggressive behavior and
resistance to current treatments display poor prognosis. NF-κB signaling pathways are …